Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
about
Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixabanPrevalence, Patterns, and Clinical Predictors of Left Ventricular Late Gadolinium Enhancement in Patients Undergoing Cardiac Magnetic Resonance Prior to Pulmonary Vein Antral Isolation for Atrial Fibrillation: A Cross-Sectional Observational StudyConcomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms.Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide.Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.Clinical development of rivaroxaban: emerging new clinical evidences?Safety of non-vitamin K antagonist oral anticoagulants - coronary risks.A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome.Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation.Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation.Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet.Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations
P2860
Q36100271-4445B85D-734D-4166-95A2-651A426D609DQ36241389-4994A12B-37B3-44FD-A32A-353321337769Q36256066-C9D987FA-032C-4F30-8B93-899A869C0955Q36713982-1DDF8CCC-65B1-4FF6-AA7F-46B7C9E54B3CQ36956791-E6718B68-867C-4575-8133-B3BF9B7EB537Q37641965-D6978152-D8EE-47F7-9C07-C6A1D5642970Q37669387-6821D61C-35DD-490B-865E-5DBBB8BAF5F3Q37699699-EB1F12D7-0091-4DB2-9A17-D9DF22F6ABD7Q38221812-85F96E52-7E94-4695-A140-A516F594FFB6Q38386998-9DC9D81A-3CFC-49CE-961B-FEC153FB4F29Q38411887-7E8E7451-8719-4CD2-A043-2AC98A862FD3Q38537785-F1F20A54-B1D0-42CA-B1A6-42855B1C01E3Q38766678-2EA6A79D-DAB2-4920-85D4-ED1430BEA282Q38770111-CB519E36-D155-46D3-B388-A8995C157398Q38812464-96D2802C-83E4-46F1-865F-C78826577DE2Q38935753-EA6C951A-A571-4942-94BD-63092CD4E85DQ38953655-DB417DFB-B97A-4BD1-92EF-C06EF32E69C1Q39023182-D322BA19-530E-4C98-B7A0-C964620AE727Q39031152-7FF27F91-2CE8-4E18-ABA5-B401F85EBD29Q39187952-5D6838EC-87AA-44F2-B44E-432D4FBB22E0Q42286343-7054B42B-D296-41EE-94D8-6570DD9B543CQ47162918-BA687CA1-411B-4C35-B81B-FD6EFBB28002Q47654635-CF1E961F-D12A-40E2-9DB0-34A6A6CCE63FQ55269457-B26A455A-D392-458D-B23D-F260BF60015AQ58796861-E1FCF299-B107-4E94-B1CC-40FF53036CC4
P2860
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@en
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@nl
type
label
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@en
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@nl
prefLabel
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@en
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@nl
P2093
P2860
P50
P921
P356
P1476
Ischaemic cardiac outcomes in ...... ults from the ROCKET AF trial.
@en
P2093
Christopher C Nessel
Daniel E Singer
Harvey D White
Keith A A Fox
Manesh R Patel
ROCKET AF Investigators
Richard C Becker
Shaun G Goodman
Susanna R Stevens
Werner Hacke
P2860
P304
P356
10.1093/EURHEARTJ/EHT428
P50
P577
2013-10-15T00:00:00Z